Skip to content

Research Use Only. Products listed are not for human or animal consumption. Statements have not been evaluated by the FDA.View full disclaimers →

Back to search
Weight LossMetabolic

Retatrutide

Retatrutide is an investigational triple agonist acting at the GLP-1, GIP and glucagon receptors, developed by Eli Lilly for obesity and metabolic disease. It is not approved by any regulator and is legally available only through its clinical trial programme.

Lowest cost / mg
$1.42/mg
at ZC Labs
Vendors listed
68
In stock
259 of 262
listings
COA reports
208
OverviewVendor ListingsBenefitsDosingEvidenceInteractionsFAQ

Vendor listings

Compare Retatrutide prices.

Size

5mg5 mg · 10 vials6mg10mg10 mg · 10 vials11mg12mg12 mg · 10 vials15 mg · 10 vials15mg20mg20 mg · 10 vials22mg24mg30mg30 mg · 10 vials40mg40 mg · 10 vials48mg50 mg · 10 vials50mg60mg60 mg · 10 vials70mg100 mg · 10 vials100mg
PricesLab tests208

Retatrutide verification

Independent third-party laboratory analysis for quality assurance.

Tracked tests208 Reports

Overview

What is Retatrutide?

Retatrutide is an investigational triple agonist acting at the GLP-1, GIP and glucagon receptors, developed by Eli Lilly for obesity and metabolic disease. It is not approved by any regulator and is legally available only through its clinical trial programme.

  • Weight Management
  • Appetite Control
  • Metabolic Health
  • Liver Fat

What the research reports

Reported benefits of Retatrutide

Outcomes described across the published Retatrutide literature and ongoing study. Read each as research context, not a promised result.

  1. 01

    Large weight loss in trials

    Phase 2 work reported dose dependent weight loss up to 24.2 percent at 48 weeks against 2.1 percent on placebo in adults with obesity. Reported in research settings.

  2. 02

    Triple receptor activation

    Activates GLP-1 for appetite control, GIP for metabolic efficiency and glucagon for energy expenditure simultaneously, a broader reach than dual agonists.

  3. 03

    Glycaemic control research

    Phase 2 trials in type 2 diabetes reported HbA1c reductions up to 2.02 percent alongside meaningful reductions in body weight. Reported in research settings.

  4. 04

    Liver fat reduction study

    A phase 2a trial in 98 patients with fatty liver disease reported liver fat down up to 82.4 percent at 24 weeks, with 86 percent reaching normal liver fat.

  5. 05

    Body composition change data

    A 2025 analysis reported total body fat mass reduced by 15 to 26 percent against placebo in people with type 2 diabetes. Reported in research settings.

Dosage and protocol

Retatrutide dosage and protocol

Trial protocols titrate from 1 mg weekly through 2, 4 and 8 mg to a 12 mg target, escalating every four weeks. The half-life is approximately six days at steady state dosing.

Route
Subcutaneous injection
Example range
1-12 mg
Frequency
Once weekly
Timing
Once weekly, same day. Escalate every four weeks to limit nausea.

Clinical evidence

Clinical evidence for Retatrutide

The published record for Retatrutide, labeled by strength so you can see what is settled and what is emerging.

Phase 2 obesity trial, 2023

Jastreboff and colleagues reported in the NEJM that 338 adults on retatrutide lost up to 24.2 percent of body weight at 48 weeks against 2.1 percent on placebo.

Source

Type 2 diabetes trial, 2023

A Lancet phase 2 trial in 281 people with type 2 diabetes reported HbA1c improved by up to 2.02 percent with body weight down by as much as 16.94 percent. Reported in the cited paper.

Source

Liver disease phase 2a study

A 2024 Nature Medicine trial in 98 patients reported liver fat down up to 82.4 percent at 24 weeks, with 86 percent reaching normal liver fat content. Reported in the cited paper.

Source

Interactions

How it pairs with other peptides

Semaglutide
Overlapping GLP-1 activity. Combining raises gastrointestinal burden with no established added benefit.
Tirzepatide
Overlapping GLP-1 and GIP activity. The two are not combined in any clinical protocol. Confidence: emerging.
Insulin therapy
Glucose lowering effects stack, so hypoglycaemia risk rises when incretin therapy is added to insulin.
Sulfonylureas
Added glucose lowering raises hypoglycaemia risk and usually calls for a dose review by a clinician.

Questions

Frequently asked questions.

What is Retatrutide?
Retatrutide is a peptide compound used in research settings. It is commonly studied for its role in weight loss, metabolic, and many researchers compare supplier quality, purity, and testing data before purchasing.
What are the research benefits of Retatrutide?
Retatrutide is often evaluated for its potential influence on signaling pathways, recovery support, and targeted research applications. Research interest varies by peptide, formulation, and study design, so buyers typically review purity, dose, and independent lab verification before choosing a source.
How does Retatrutide work?
Like other research peptides, Retatrutide is typically studied for how it interacts with specific biological pathways and receptor systems. In practice, the way it is formulated, dosed, and tested matters as much as the compound itself, which is why verified suppliers and transparent COAs are important.
Is Retatrutide for research use only?
Yes, products like Retatrutide are generally intended for research, laboratory, or educational use and are not marketed as approved human therapeutics. Always follow local laws, lab safety practices, and institutional requirements before handling or studying any peptide.
What should I look for before buying Retatrutide?
Key checks include verified COA data, peptide form and concentration, supplier reputation, stock status, and cost per mg. Comparing pricing and testing records side-by-side helps reduce the risk of buying an under-tested or misrepresented product.

The directory

All vendors.

83 listed

Show all 83 vendors

Newsletter · Quarterly

Join the Inner Circle.

Get notified about new lab results, price drops and supplier coupons before everyone else.

We respect your privacy. No spam.